AI for Personalized Health

August 2017 Webinar - Cohen Veterans Bioscience

AI for Personalized Health

Monday, August 21st, 2017, at 12pm noon ET

Daniela Brunner, PhD
Founder and President, Early Signal Foundation

Webinar Summary

The Digital Health revolution is well underway, with an exponential number of players entering and contributing to the emerging era of “Connected Care”. Artificial intelligence can bridge the gap between a “health care system-centric” and “patient-centric” modality of care through user-friendly access to health records and intelligent tools, that enable patient engagement, care plan adherence, and informed health self-management.

In this webinar, Dr. Brunner will discuss the Early Signal platform (EaSi), which enables innovative modes of healthcare delivery via the secure capture, management, analysis, and delivery of highly-actionable healthcare information across the healthcare continuum. Through artificial intelligence approaches, EaSi utilizes data from wearable and home sensor technology to remotely monitor patient health status including sleep-architecture, gait and stereotypes, provide evidence-based clinical decision-support, and promote positive outcomes for health and neurodevelopmental, neurodegenerative, and psychiatric disorders.

Dr. Brunner will explore the potential of this device-agnostic analytics platform to provide surrogate measures to inform clinical decision making, enable post-treatment feedback, promote positive outcomes, and optimize resource utilization for care management and delivery.



About Daniela Brunner, PhD
Founder and President, Early Signal Foundation

Daniela Brunner, PhDDaniela Brunner, PhD, is the Founder and President of Early Signal Foundation. She has worked in the analysis of models of developmental, psychiatric, and neurodegenerative disease models for the last 20 years. A major focus of her work has been establishing and automatizing rodent behavioral tests and novel high throughput preclinical platforms using computer vision and machine learning algorithms to comb behavioral signatures for phenotyping, drug screening, and systems biology approaches. As Senior Vice-President of Behavioral Research at PsychoGenics, she was in charge of large projects focused on back-translation of anti-smoking cessation medication, preclinical cognitive assessment, and studies in neurodegeneration, psychiatry, and autism. The current overarching goal of Daniela’s work is to establish analytical systems that integrate behavioral and “omics” readouts for the discovery of novel therapeutics. She aims to develop new tools for the analysis of health signatures in humans, particularly for rare disorders, with a special interest in connecting genomic information with behavioral domains, especially those passively captured with wearable sensors.